Bioluminescence Imaging of Stem Cell-Based Therapeutics for Vascular Regeneration by Huang, Ngan F. et al.
Theranostics 2012, 2(4) 
 
 
http://www.thno.org 
346 
T Th he er ra an no os st ti ic cs s   
2012; 2(4):346-354. doi: 10.7150/thno.3694 
Review 
Bioluminescence Imaging of Stem Cell-Based Therapeutics for Vascular 
Regeneration 
Ngan F. Huang, Janet Okogbaa, Anna Babakhanyan, John P. Cooke  
Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA  
 Corresponding author: John P Cooke, MD, PhD, Division of Cardiovascular Medicine, Stanford University, 300 Pasteur Drive, Stanford, 
CA 94305-5406. Fax Number: 650-723-8392; Telephone Number: 650-723-6459; Email: john.cooke@stanford.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2011.10.23; Accepted: 2012.01.18; Published: 2012.04.01 
Abstract 
Stem cell-based therapeutics show promise for treatment of vascular diseases. However, the 
survival of the cells after in vivo injection into diseased tissues remains a concern. In the advent 
of non-invasive optical imaging techniques such as bioluminescence imaging (BLI), cell locali-
zation and survival can be easily monitored over time. This approach has recently been applied 
towards monitoring stem cell treatments for vascular regeneration of the coronary or pe-
ripheral arteries. In this review, we will describe the application of BLI for tracking trans-
planted stem cells and associating their viability with therapeutic efficacy, in preclinical disease 
models of vascular disease. 
Key words: bioluminescence, embryonic stem cell, induced pluripotent stem cell, peripheral arte-
rial disease, myocardial infarction, vascular regeneration 
Introduction 
Vascular regenerative therapies for the coronary 
or  peripheral  vasculature  aim  to  restore  pulsatile 
flow,  stimulate  neovasculature  formation,  and  en-
hance vascular function. Stem cells are a promising 
cell source for vascular repair because of their high 
replicative  capacity  and  ability  to  differentiate  into 
vascular  cells  that  incorporate  into  existing  vessels, 
form  neovessels,  or  release  angiogenic  factors.  Alt-
hough stem cells can be derived from numerous tis-
sues and have varied differentiation potential, a uni-
versal concern is their long term survival in diseased 
tissues. With the advent of non-invasive techniques 
such as bioluminescence imaging (BLI), it is now pos-
sible to track cell localization and quantify cell sur-
vival in vivo. BLI is a highly sensitive technique that 
has  been  recently  applied  towards  tracking  of  cell 
survival and localization upon stem cell delivery for 
vascular repair (Table 1). When used in conjunction 
with assessments of tissue function, BLI can be used 
to correlate therapeutic efficacy with cell persistence, 
as well as in identifying optimal cell dosing. In this 
review,  we  will  describe  the  application  of  BLI  for 
tracking transplanted stem cells and associating their 
viability with therapeutic efficacy, in preclinical dis-
ease models of vascular disease. 
Therapeutic Stem Cells for Vascular Regen-
eration 
Therapeutic  cells  for  vascular  regeneration  can 
be broadly classified as pluripotent stem cells, mul-
tipotent stem/progenitor cells, and somatic cells (Fig. 
1A). Each class of cells is distinguished based on the 
expression of known immunophenotypic markers as 
well as their differentiation potential. Stem cells can 
be derived from a variety of sources from adult, neo-
natal, fetal, and embryonic tissues. 
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Table 1. BLI imaging of therapeutic stem and progenitor cells for vascular regeneration. 
Cell Type  Site of Repair  Therapeutic Outcome 
 
Reference 
ASC  Ischemic myocardium  ↑Cardiac function 
↑Angiogenesis 
↓ Apoptosis 
Differentiation 
 
[41, 42] 
BM MSC  Ischemic limb  ↑Angiogenesis 
↓ Muscle damage 
[38] 
BM MSC and HUVEC  Subcutaneous  ↑Angiogenesis 
↑Cell survival 
[40] 
CD44+ cells  Ischemic myocardium  ↑Cardiac function 
↑Angiogenesis 
[37] 
ESC-EC  Ischemic limb  ↑Angiogenesis 
↑Blood perfusion 
[43] 
  Ischemic myocardium  ↑Cardiac function 
↑Angiogenesis 
[45, 46, 48] 
ESC-MSC  Ischemic limb  ↑Angiogenesis (transient) 
↑Proliferation (transient) 
[39] 
iPSC- EC  Ischemic limb  ↑Angiogenesis 
↑Blood perfusion 
[12] 
Abbreviations: adipose-derived stem cells (ASC); none marrow-derived mesenchymal stem cells (BM MSC); human umbilical vein endo-
thelial cell (HUVEC), embryonic stem cell-derived endothelial cells (ESC-EC); embryonic stem cell-derived mesenchymal stem cells 
(ESC-MSC); induced pluripotent stem cell-derived endothelial cells (iPSC-EC) 
 
 
 
Figure 1. Application of stem cell therapeutics for bioluminescence imaging. A. Types of therapeutic cells include embryonic 
stem cells (ESC), bone marrow mesenchymal stem cells (BM-MSC), and primary endothelial cells (EC). B. An example of a viral construct 
to confer bioluminescence and fluorescence imaging. C. Bioluminescence intensity with increasing cell density. D. Quantification of 
bioluminescence vs cell density showing linear correlation. Theranostics 2012, 2(4) 
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Pluripotent  stem  cells.  Among  the  different 
types  of  stem  cells,  pluripotent  stem  cells  have  the 
greatest differentiation potential as they can give rise 
to committed cell lineages comprising all three germ 
layers. Furthermore, pluripotent stem cells have infi-
nite self-renewal capacity. To date there are only two 
types  of  known  pluripotent  stem  cells,  namely  em-
bryonic  stem  cells  (ESCs)  and  induced  pluripotent 
stem cells (iPSCs). ESCs are derived from the inner 
cell mass of blastocysts [1], whereas iPSCs are gener-
ated by reprogramming somatic cells by the induced 
expression of specific transcriptional factors, as first 
described by Shinya Yamanaka and colleagues in 2006 
[2]. Ethical concerns regarding the generation of ESCs 
from  human  embryos,  and  the  hurdle  of  ESC  im-
munocompatibility,  have  increased  enthusiasm  for 
iPSC-based  cell  therapy.  Nevertheless,  the  clinical 
application of therapies based on ESCs is farther along 
in development than those using iPSCs. Geron was 
the first company to gain FDA approval for a clinical 
trial using human ESC-derived oligodendrocytes for 
spinal cord repair [3]. More recently, Advanced Cell 
Technologies has received FDA approval for clinical 
trials  using  human  ESC-derived  lineages  for  treat-
ment  of  Stargardt  disease  and  age-related  macular 
regeneration, and other companies are nearing sub-
mission  for  IND  approval,  such  as  Viacyte  with  a 
product for type 1 diabetes [4]. 
Since  iPSCs  can  be  derived  from  a  variety  of 
tissues  and  have  high  replicative  capacity,  they  are 
potentially an unlimited source of autologous thera-
peutic  cells.  Already,  pre-clinical  studies  using 
iPSC-derived cells have shown promise for treatment 
of  sickle  cell  anemia,  Parkinson’s  disease,  be-
ta-thalassemia, and peripheral arterial disease (PAD) 
[5-7]. However, some concerns have been raised re-
garding the chromosomal and point mutations, and 
incomplete  transgene  silencing,  that  could  lead  to 
oncogenic potential, as well as functional differences 
compared by comparison to ESCs [8-12]. These con-
cerns  have  been  addressed  in  part  by  more  recent 
studies  indicating  that  these  genetic  and  epigenetic 
abnormalities may be obviated with careful genera-
tion,  culture  and  selection  of  iPSCs  [13].  Although 
pluripotent  stem  cells  themselves  are  capable  of 
forming teratomas in vivo, once they are differentiated 
into lineage committed cell fates, it is likely that the 
differentiated progeny will maintain their phenotype 
in vivo.  
Multipotent  stem  cells.  Multipotent  stem  and 
progenitor cells and can be derived from a variety of 
adult and fetal sources, including bone marrow, adi-
pose  tissue,  muscle,  lung,  and  pancreas  [14].  Mul-
tipotent  stem  cells  are  identified  based  on  their  ex-
pression of multiple cell surface glycoproteins, as no 
one antigen is sufficient. Furthermore, differences in 
tissue origin also affect their phenotypic markers, as 
bone  marrow-derived  mesenchymal  stem  cells 
(MSCs) have slightly different surface marker expres-
sion  when  compared  to  adipose-derived  stem  cells 
(ASCs)  [15]. Unlike pluripotent stem cells, multipo-
tent stem cells have limited self-renewal capacity and 
can  only  give  rise  to  limited  types  of  committed 
progeny. For example, hematopoietic stem cells give 
rise to all blood lineages of the bone marrow. Since 
multipotent stem cells can be harvested autologously, 
and  because  their  application  has  lower  regulatory 
hurdles,  clinical  trials  of  multipotent  stem  cells  are 
furthest  advanced  in  comparison  to  iPSC  or  ESC 
based therapies. In most clinical trials of multipotent 
adult stem cells, the cells are simply harvested and 
administered directly into the diseased tissue, where 
it is assumed that in-vivo cues can direct their cellular 
responses,  lineage  specification,  and  incorporation 
into the tissue.  
Besides stem and progenitor cells, somatic cells 
such as primary endothelial cells have been demon-
strated  to  enhance  blood  flow  and  angiogenesis  in 
ischemic tissues, in part by incorporating into existing 
vasculature and forming neovessels [16, 17]. Howev-
er,  patients  with  cardiovascular  diseases  may  have 
dysfunctional endothelial cells, which limit the ther-
apeutic  efficacy  of  cell  transplantation.  Another  ap-
proach may be to transdifferentiate a somatic cell (eg. 
a fibroblast) into an endothelial cell. Although trans-
differentiation to generate vascular cells has not yet 
been reported, transdifferentiation of fibroblasts into 
neurons, or into cardiomyoblasts, has been achieved 
[18, 19]. 
Clinical Application of Stem Cells 
 Clinical trials using stem cells in patients with 
PAD and coronary heart disease to augment vascular 
regeneration have been limited to adult human bone 
marrow  mononuclear  cells,  MSCs,  or  endothelial 
progenitor cells. These stem cells have shown some 
promise of therapeutic benefit. In patients with PAD, 
small  clinical  trials  using  adult  stem  cells  (usually 
bone marrow derived mononuclear cells) have shown 
modest  improvements  in  limb  hemodynamics, 
wound healing, and/or functional capacity (usually 
assessed by treadmill walking time) [20, 21]. Proposed 
mechanisms of benefit include the secretion of angi-
ogenic cytokines, differentiation into vascular lineage, 
cell  fusion,  and/or  incorporation  into  the  existing 
tissue to improve tissue function [21, 22]. Larger ran-
domized clinical trials are needed to confirm the ben-
efit and to address mechanisms. However, since adult Theranostics 2012, 2(4) 
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stem cells such as endothelial progenitor cells are re-
duced in number and impaired in patients with car-
diovascular risk factors [23, 24], alternative therapeu-
tic cell sources such as iPSCs are promising, especially 
in  light  of  recent  developments  in  the 
non-DNA-based generation of iPSCs [25]. 
In Vivo Bioluminescence Imaging of Thera-
peutic Cells for Vascular Regeneration 
 Although  data  from  clinical  trials  provide 
promise for stem cell therapy, the optimal cell type, 
cell  dosing,  and  route  of  administration  is  still  un-
known. Therefore, non-invasive cell tracking methods 
such as BLI provide added information regarding cell 
survival and localization to facilitate an understand-
ing of any benefit, and to optimize treatment. We now 
discuss the principle of BLI and its application in pre-
clinical studies of stem cell delivery.  
Application  of  imaging  modalities  to  elucidate 
the fate of stem cells after in vivo transplantation for 
vascular disease is at an early stage. Recently, BLI has 
been applied for tracking the localization and survival 
of stem and progenitor cells in vivo for vascular re-
generation. This approach involves genetically mod-
ifying the therapeutic cells to confer expression of a 
bioluminescent  reporter  enzyme,  most  commonly 
firefly luciferase (fluc) (Fig 1B). When fluc binds its 
substrate,  D-luciferin,  an  oxidation  reaction  occurs 
resulting in the emission of photons with peak inten-
sity near 560 nm [26]. The bioluminescence intensity 
correlates  directly  with  cell  density,  and  this  rela-
tionship  allows  for  relative  quantification  of  cell 
numbers  in  vivo  and  in  vitro  (Fig.  1C-D).  A  recent 
modified  version  of  the  fluc  gene,  known  as  luc2, 
provides improved photon emission and greater sen-
sitivity, even capable of non-invasively detecting sin-
gle cells in vivo [27].  
In addition to fluc, a variety of luciferases de-
rived from other organisms have been optimized to 
display  unique  spectral  properties  upon  excitation. 
Though  fluc  remains  the  preferred  enzyme  for  BLI 
due  to  the  high  intensity  of  light  it  produces,  the 
availability of multiple luciferases allows for the sim-
ultaneous  monitoring  of  numerous  biological  pro-
cesses when the appropriate filter and substrate com-
binations are applied [28]. Two particular luciferases 
under  development  are  Renilla  and  Gaussia.  Alt-
hough their smaller size and ATP-independent exci-
tation  are  advantageous  over  fluc,  their  substrate, 
coelenterazine is rapidly metabolized and limited in 
biodistribution capabilities when compared to lucif-
erin [29, 30]. These enzymes produce blue light with 
peak emission near 480 nm [29]. Light at this wave-
length  is  more  susceptible  to  tissue  scattering  and 
background signal. However, red-shifted variants of 
Renilla have less endogenous background signal and 
may have enhanced utility in small-animal imaging 
[31]. 
The primary advantage of BLI over other imag-
ing modalities is its high detection sensitivity and low 
background signal. Unlike fluorescence imaging, BLI 
does not require external illumination of the tissue. As 
a result, photon emission from endogenous particles 
is reduced. This high signal-to-noise ratio enables the 
reliable detection of quantities as low as single trans-
planted cells at specific anatomical sites, when using 
luc2 [27]. In addition to superior sensitivity and spec-
ificity,  the  non-invasive  nature  of  BLI  allows  for 
quantitative assessment of viable cell numbers in liv-
ing organisms that can be carried out cost-effectively 
over  multiple  time  points.  This  feature  provides  a 
great advantage over traditional histological evalua-
tion of transplanted cells that requires euthanasia of 
animal subjects. For example, when implanted within 
the  ischemic  hindlimb  with  biocompatible  matrix 
proteins,  we  could  non-invasively  monitor  the  sur-
vival  of  human  iPSC-derived  endothelial  cells  (Fig. 
2A) for at least 14 days (Fig. 2B). 
One limitation of BLI is attenuation and scatter-
ing of light by tissues. For each centimeter of tissue, 
hemoglobin, as well as other endogenous molecules, 
may reduce optical signals by a factor of 10 [32]. As a 
result,  sources  that  are  nearer  to  the  surface  of  the 
subject appear to have brighter signals in comparison 
to  more  internal  sources.  Additionally,  because  the 
images generated by BLI are two-dimensional, signals 
from overlapping anatomic structures are summated 
and  cannot  be  quantified  individually.  However, 
technological  advances  in  optical  imaging  over  the 
past  decade  are  beginning  to  address  these  issues. 
Three-dimensional  diffuse  tomographic  reconstruc-
tions, which can be obtained using fluorescence mo-
lecular  tomography,  allow  for  both  molecular  and 
structural  data  to  be  gathered  simultaneously  [33]. 
Moreover, the sensitivity and resolution of BLI images 
has improved dramatically with the advent of highly 
sensitive charge-couples device detectors, specialized 
filters, and enhanced spectral analysis techniques [34].  
Although these advances enable BLI to serve as a 
powerful tool for the investigation of biological pro-
cesses and the development of cell-based therapies in 
preclinical models, the present risks associated with 
genetically modifying cells to express a biolumines-
cent reporter preclude the use of BLI in human sub-
jects  at  this  time,  The  development  of  DNA-free 
methods of inducing luciferase expression, including 
modified mRNA [35] or protein [36] approaches, may 
allow  for  the  expansion  of  BLI  into  clinical  experi-Theranostics 2012, 2(4) 
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mentation although the current limitations of tissue 
penetration in large animals and humans will need to 
be overcome. . 
Adult  stem  and  progenitor  cells.  BLI  has  al-
ready played a critical role in assessing cell localiza-
tion and survival in preclinical studies of adult stem 
and progenitor cell-based therapies for vascular dis-
ease. An early study assessed the in vivo longevity of 
human CD34+ progenitor cells derived from periph-
eral blood when injected into the peri-infarct region of 
infarcted murine myocardium. The cells were stably 
transduced with a triple fusion construct containing 
fluc, enhanced green fluorescent protein (eGFP), and 
human herpes simplex virus type 1-thymidine kinase 
(HSV1-tk)  to  enable  multi-modal  imaging  by  BLI, 
fluorescence  microscopy,  and  positron  emission  to-
mography  (PET),  respectively  [37].  BLI  tracking  re-
vealed an increase in cell numbers in the infarct scar 
over  the  course  of  the  first  2  weeks,  followed  by  a 
gradual decline in cell numbers for the next 50 weeks. 
Notably,  cell  signal  persisted  for  up  to  52  weeks, 
based on BLI, and the localization of cells in the scar 
was further verified by PET imaging. Ejection fraction 
was significantly improved by CD34+ cell therapy as 
early as one  week after injection, and the  improve-
ment could be  sustained for up to 52 weeks, when 
compared to sham-operated mice. The mechanism of 
action  appeared  to  be  due  to  angiogenesis  and/or 
paracrine  factors,  since  in  vivo  delivery  of  vascular 
endothelial  growth  factor  (VEGF)  antibody  blocked 
the improvement in cardiac function after cell thera-
py. 
 In a murine model of PAD, the femoral artery of 
mice  was  ligated  to  induce  hindlimb  ischemia,  and 
BLI  was  used  to  assess  the  effect  of  bone  mar-
row-derived  MSCs  on  vascular  perfusion  [38].  De-
rived from transgenic mice expressing GFP and fluc, 
MSCs or fibroblasts were  injected into the ischemic 
limbs of syngeneic mice. Longitudinal monitoring of 
cell survival using BLI demonstrated that MSCs per-
sisted for up to 6 days, whereas half of the injected 
fibroblast  remained  after  22  days.  Despite  their 
short-term survival, MSCs improved capillary density 
and  reduced  ischemic  muscle  damage,  when  com-
pared  to  the  groups  receiving  fibroblasts  or  saline. 
However,  the  MSCs  did  not  appear  to  differentiate 
into vascular lineages, based on the absence of colo-
calized GFP expression with endothelial markers. The 
mechanism of improvement may be in part due to the 
ability of MSCs to secrete higher levels of VEGF under 
hypoxic conditions than under normoxic conditions, 
whereas fibroblasts manifested reduced secretion of 
VEGF under hypoxia. 
 
Figure  2.  Transduction  and  in  vivo  delivery  of  human  induced  pluripotent  stem  cell-derived  endothelial  cells 
(iPSC-ECs). A. Purifed iPSC-ECs were transduced with a fusion reporter construct encoding fluc and GFP. Immunofluorescence staining 
demonstrates about 30% positive expressing GFP while coexpressing endothelial phenotypic marker, VE-cadherin. B. When delivered into 
the ischemic hindlimb with biocompatible matrix proteins, the cells could be tracked using BLI for at least 14 days. Theranostics 2012, 2(4) 
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In a study by Laurila et al, BLI was utilized to 
observe  the  engraftment  of  transplanted  stem  cells 
into  ischemic  hindlimb  tissue  [39].  Human 
ESC-derived  MSCs  or  adult  human  bone  mar-
row-derived  MSCs  were  locally  transplanted  into  a 
rat hindlimb ischemia model. The ESC-derived MSCs 
were genetically engineered to express GFP and lu-
ciferase. Using BLI, it was determined that only about 
1% of transplanted MSCs persisted for 3 days after 
delivery. Whole body imaging revealed no biolumi-
nescence signal in any other tissues than at the site of 
injection,  confirming  no  migration  of  transplanted 
cells.  Despite  limited  engraftment,  the  ESC-  or 
BM-derived MSCs increased angiogenesis and skele-
tal muscle cell proliferation after 3 days. At later time 
points,  there  was  no  significant  difference  in  these 
endpoints by comparison to the control ischemic an-
imals.  The  authors  concluded  that  the  short-term 
benefits in angiogenesis and proliferation were due to 
the activation of endogenous signaling pathways ra-
ther than human cells.  
 In  immunocompromised  mice,  enhanced  BLI 
was  used  to  study  the  effects  of  human  bone  mar-
row-derived MSCs on the survival of human endo-
thelial  cells  [40].  In  comparison  to  matrigel  plugs 
containing endothelial cells alone, mixtures of MSCs 
with endothelial cells had higher BLI signal intensity 
after 120 days, as well as a greater number of func-
tional  neovessels  that  contained  blood  cells.  Histo-
logical  analysis  revealed  that  the  neovessels  in  the 
coculture group had greater numbers of vessels lined 
by  human  endothelial  cells,  when  compared  to  the 
plugs containing human endothelial cells alone.  
 Adipose  tissue  is  another  promising  source  of 
therapeutic  cells  for  vascular  repair.  Bai  et al.  com-
pared the therapeutic efficacy and survival of freshly 
isolated  human  adipose  tissue-derived  cells  in  con-
trast  to  cultured  ASCs,  in  a  SCID  mouse  model  of 
myocardial infarction [41]. Cultured ASCs were ho-
mogeneous  in  their  expression  of  stromal  stem  cell 
phenotypic markers, whereas freshly isolated human 
adipose tissue-derived cells appeared to be a hetero-
geneous population containing CD44+ stromal stem 
cells,  as  well  cells  staining  for  CD34  (46%),  CD31 
(10%), and smooth muscle α-actin (4%). When injected 
into  the  peri-infarct  region,  either  freshly  isolated 
human adipose tissue-derived cells or cultured ASCs 
improved  cardiac  function  as  assessed  by  ejection 
fraction  and  end  systolic  volume  after  4  weeks,  in 
association  with  increased  vascular  density  and  re-
duced apoptosis in the myocardium. To assess the in 
vivo  survival  of  ASCs  in  the  ischemic  myocardium, 
the cells were lentivirally transduced with a double 
fusion construct encoding for GFP and fluc under the 
control of a long-terminal-repeat promoter. Temporal 
profiling  using  BLI  demonstrated  that  cell  survival 
initially  decreased  over  the  course  of  2  weeks,  fol-
lowed  by  a  gradual  increase  in  cell  density.  At  16 
weeks  following  implantation  the  human  adipose 
tissue-derived cells were localized only to the heart, as 
imaging of other organs such as the lung, liver, and 
spleen did not show detectable bioluminescent signal. 
This work highlights the utility of BLI in monitoring 
cell survival, and in providing insights into the effi-
cacy  of  human  adipose  tissue-derived  cells  or  cul-
tured ASCs in this model. In a related study by Bai et 
al.  [42],  the  authors  reported  that  human  ASCs  se-
creted  angiogenic  growth  factors,  basic  fibroblast 
growth factor (bFGF), and insulin-like growth factor-1 
in the ischemic myocardium. It is likely that the en-
hancement of myocardial function following admin-
istration of ASCs was attributable to paracrine effects, 
rather than incorporation of the cells into the ischemic 
tissue.   
Pluripotent  stem  cells.  Pluripotent  stem 
cell-derived  lineages  are  an  attractive  form  of  cell 
therapy  because  of  their  unlimited  self-renewal  ca-
pacity. Both ESC-derived and iPSC-derived ECs may 
persist in, and enhance neovascularization of, the is-
chemic limb or myocardial tissue. We have previously 
used BLI and laser Doppler spectroscopy to study the 
effect  of  syngeneic  ESC-ECs  in  a  murine  hindlimb 
ischemia  model  [43].  ESC-derived  ECs  enhanced 
perfusion when delivered by intra-arterial and intra-
venous delivery, but not by intramuscular injection, 
as  compared  to  saline-treated  animals.  Concurrent 
with the intra-arterial or intramuscular administration 
of ESC-EC, a BLI signal was observed in the ischemic 
limb that decayed over time. When cells were deliv-
ered  intravenously  the  cells  initially  lodged  in  the 
lung region, as detected by BLI. Intriguingly, over a 
period  of  several  days,  the  BLI  signal  disappeared 
from the lung, and began to increase in the ischemic 
(but not the contralateral unoperated) hindlimb. This 
observation  suggested  that  the  ESC-ECs  initially 
trapped in the lung were able to home to the ischemic 
limb. Unlike ESCs, the ESC-ECs could not be detected 
in spleen, lung, and liver tissue samples at 2 weeks 
after cell delivery. A significant improvement in blood 
perfusion was observed with both intra-arterial and 
intravenous administration of the cells. The beneficial 
effect of cells administered intravenously was delayed 
by  comparison  to  intra-arterial  administration,  and 
was temporally concordant with their homing to the 
ischemic hindlimb. The observations are most likely 
explained by a paracrine angiogenic effect of the cells 
after they become localized to the ischemic limb. Of 
note, parental ESCs did not home to the ischemic limb Theranostics 2012, 2(4) 
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when  injected  intravenously,  nor  did  they  improve 
perfusion when administered by any route. 
We recently used BLI to optimize an intramus-
cular delivery strategy using human fluc-expressing 
iPSC-derived ECs for treatment of hindlimb ischemia 
in  SCID  mice  [44].  The  cells  were  delivered  in  two 
doses on days 0 and 7 after the induction of hindlimb 
ischemia. Based on BLI, there was a gradual decrease 
in  cell  viability  over  the  course  of  the  first  7  days. 
Accordingly, we modified the delivery strategy so as 
to provide a second injection of cells on day 7. Over 
the course of the following week the BLI signal de-
clined  gradually,  indicating  some  loss  of  cells  over 
time.  Nevertheless,  the  repeated  injection  of 
iPSC-derived ECs modestly enhanced limb perfusion, 
as  corroborated  by  capillary  density  analysis.  Alt-
hough  rare  iPSC-ECs  were  observed  to  incorporate 
into  existing  vessels,  it  is  likely  that  the  enhanced 
perfusion was largely due to a paracrine effect, as the 
iPSC-ECs  could  generate  angiogenic  factors  in  re-
sponse to hypoxia.  
BLI has also been utilized to quantify the viabil-
ity of ESC-derived cells injected into the peri-infarct 
region  after  experimental  myocardial  infarction. 
When murine ESC-derived ECs were injected into the 
ischemic myocardium of syngeneic mice, the cell sur-
vival decreased most sharply within one week, with 
only ~1% of the signal remaining after 8 weeks, when 
normalized to the signal intensity of day 2 [45]. Alt-
hough  few  remaining  ESC-derived  ECs  could  be 
identified  histologically in native vessels,  there  was 
significant  improvement  in  capillary  density,  con-
comitant with higher fractional shortening and ejec-
tion fraction as measures of cardiac function after 8 
weeks. In contrast to ESC-derived ECs, ESCs showed 
marked differences in cell survival and cardiac func-
tion when injected into ischemic scars. There was a 
transient decrease in cell viability for the first week, 
followed by a robust proliferation for up to 3 weeks, 
based  on  BLI.  The  increase  in  BLI  signal  was  con-
sistent  with  the  formation  of  teratomas  resembling 
cells of all three germ layers. Unlike ESC-derived ECs, 
ESCs did not improve cardiac function.  
Similar  to  murine  ESC-derived  ECs,  human 
ESC-derived ECs also manifested poor survival when 
injected into the peri-infarct region of SCID mice [46]. 
Based  on  BLI,  human  ESC-derived  ECs  declined  in 
cell number most rapidly during the first week, re-
sulting in about 6% survival after one week and 1% 
after 8 weeks, when normalized to cell numbers after 
2  days.  The  loss  of  transplanted  cells  could  in  part 
explain the minimal effect of the cells on microvascu-
lar density. Based on immunofluorescence staining of 
histological  sections,  some  of  the  remaining 
ESC-derived ECs localized in the host vessels. Unlike 
the  long-term  efficacy  of  murine  ESC-derived  ECs, 
human ESC-derived ECs appeared to improve cardiac 
function based on quantification of fractional short-
ening after 2 weeks, but the therapeutic benefit was 
lost after 8 weeks. These results suggest that human 
ESC-derived  ECs  injected  into  the  ischemic  murine 
myocardium  do  not  incorporate  well  into  the  host 
vasculature and have a minimal and transient effect 
on cardiac function. 
One approach to further enhance the angiogenic 
capacity and survival of ESC-derived ECs is to stim-
ulate them with a trophic small molecule or growth 
factor at the time of administration. Stimulation of the 
EC  nicotinic  acetylcholine  receptor  previously  has 
been shown to stimulate endothelial proliferation and 
tube-like formation in vitro and to enhance angiogen-
esis  and  ischemic  limb  perfusion  in  vivo  [47].  At 
physiological concentrations, nicotine could activate 
nicotinic  acetylcholine  receptors  in  human 
ESC-derived ECs and promote cell survival and pro-
liferation in vitro [48]. When physiological concentra-
tions  of  nicotine  were  then  introduced  into  the 
drinking water of SCID mice after injection of human 
ESC-derived  ECs  into  the  infarct  scar,  cell  survival 
was significantly improved for up to 6 weeks when 
compared to animals treated with cells in the absence 
of nicotine. Furthermore, activation of nicotinic ace-
tylcholine  receptors  stimulated  angiogenesis,  as 
quantified by significantly higher microvascular den-
sity.  The  enhancement  in  neovascularization  was 
partly due to upregulation of bFGF and VEGF gene 
expression  and  by  phosphorylation  of  MAPK  and 
Akt. 
Hurdles to stem cell therapy for vascular re-
generation 
Stem cells are a promising reagent for vascular 
repair, but many obstacles need to be overcome before 
they can be widely used clinically. As illustrated by 
BLI and other non-invasive imaging techniques, cell 
viability of transplanted cells in ischemic tissues re-
mains  major  concern.  Although  the  aforementioned 
studies suggest that the cells can exert a therapeutic 
effect even without prolonged survival, strategies to 
enhance  viability  using  survival  factors  (ie  HIF1α, 
Akt,  bcl2)  may  provide  additional  benefit.  Further-
more,  the  addition  of  soluble  factors  and 
three-dimensional extracellular matrices may further 
promote cell survival and/or angiogenesis. 
 With respect to the in vivo safety of stem cells, 
there are additional cautions in the use of cells de-
rived  from  pluripotent  stem  cells.  Therefore,  new 
strategies for non-integrative induction of pluripoten-Theranostics 2012, 2(4) 
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tiality,  enhanced  culture  conditions  using  xeno-free 
reagents,  and  improved  measures  of  depleting  the 
therapeutic  cells  of  any  pluripotent  stem  cells  will 
improve the safety of these cells. For example, a recent 
study  demonstrates  that  cell  surface  marker  an-
ti-stage-specific  embryonic  antigen  (SSEA)-5,  which 
binds to H type-1 glycans, could efficiently deplete a 
mixed cell population of pluripotent cells [49]. In the 
development of new stem cell-based therapies, BLI or 
other non-invasive imaging approaches will become 
increasingly important in providing cell survival in-
formation in pre-clinical models. With a greater un-
derstanding of stem cell generation, purification, and 
the  mechanism  of  therapeutic  involvement,  stem 
cell-based therapeutics will ultimately be realized. 
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